BriaCell Therapeutics Announces Pricing of Public Offering
PHILADELPHIA and VANCOUVER, British Columbia, Feb. 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care,
BriaCell Therapeutics Corp. (BCTX, BCTXW) is down by 4.71 percent during Monday morning trading, following the announcement of a ...
H.C. Wainwright analyst Emily Bodnar increased the price target for Briacell Therapeutics (NASDAQ:BCTX) to $32 from the previous $15, while maintaining a Buy rating on the stock. The company, ...
Detailed price information for Briacell Therapeutics Corp (BCT-T) from The Globe and Mail including charting and trades.
Therapeutics trading halted, volatility trading pauseMaximize Your Portfolio with Data Driven Insights:Leverage the ...
Investing.com -- BriaCell Therapeutics Corp. (NASDAQ: BCTX ...
Lung metastasis (from metastatic breast cancer) resolved - after only 2 months (4 doses) of treatment with Bria-OTS™ ...
The deal priced below last closing price of $5.04. ThinkEquity is acting as sole book running manager for the offering.Maximize Your ...
费城和不列颠哥伦比亚省温哥华讯 - 专注于癌症免疫疗法的临床阶段生物技术公司BriaCell Therapeutics Corp.今日宣布计划进行普通股的尽力公开发售。该公司目前市值为250万美元，EBITDA为-422万美元，正积极寻求加强其财务状况。此次发售的完成和具体条款将取决于市场条件，目前尚无法确定发售是否能够完成及其具体细节。
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback